Despite remarkable progress in the treatment of hepatitis C virus (HCV) infection, it remains
a significant global health burden, necessitating the development of an effective prophylactic …

Hepatitis C virus (HCV) remains a significant global health challenge. Approximately 50
million people were living with chronic hepatitis C based on the World Health Organization …

As direct-acting antiviral (DAA) therapy costs fall and eligibility criteria are relaxed, people
who inject drugs (PWID) will increasingly become eligible for HCV treatment. Yet eligibility …

Background Colonization and colonial systems have led to the overrepresentation of
Indigenous people impacted by substance use and HCV infection in Canada. It is critical to …

Background People who inject drugs (PWID) living with HIV are a priority population for
eliminating hepatitis C virus (HCV) as a public health threat. Maximizing access to HCV …

Background Multiple barriers for accessing hepatitis C virus (HCV) treatment were identified
during the interferon-based (IFN) treatment era for people who inject drugs (PWID). Whether …

Conclusions: Current risk-based screening, and subsequent treatment, will be inadequate to
achieve WHO goals. With extensive scale-up in screening, and treatment, the mortality target …

This observational study included all patients undergoing HCV treatment with direct-acting
antiviral (DAA)-based therapy between May 2020 and September 2023 at the Dolj County …

Hepatitis C virus (HCV) is one of the leading causes of liver disease and is responsible for
massive health and economic burden worldwide. The disease is asymptomatic in its early …

Hepatitis C virus (HCV) remains a significant global health challenge. Approximately 50
million people were living with chronic hepatitis C based on the World Health Organization …